Dianthus Therapeutics (DNTH) FCF Margin: 2022-2025
Historic FCF Margin for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to -7,717.17%.
- Dianthus Therapeutics' FCF Margin fell 673688.00% to -7,717.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -3,561.63%, marking a year-over-year decrease of 238686.00%. This contributed to the annual value of -1,255.57% for FY2024, which is 5267.00% up from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' FCF Margin is -7,717.17%, which was up 37.78% from -12,403.11% recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' FCF Margin registered a high of 1,399.91% during Q3 2022, and its lowest value of -12,403.11% during Q2 2025.
- Moreover, its 3-year median value for FCF Margin was -2,059.60% (2023), whereas its average is -3,132.05%.
- In the last 5 years, Dianthus Therapeutics' FCF Margin spiked by 71,296bps in 2024 and then plummeted by 1,162,238bps in 2025.
- Dianthus Therapeutics' FCF Margin (Quarterly) stood at -755.74% in 2022, then tumbled by 202,923bps to -2,784.98% in 2023, then spiked by 71,296bps to -2,072.02% in 2024, then crashed by 673,688bps to -7,717.17% in 2025.
- Its FCF Margin was -7,717.17% in Q3 2025, compared to -12,403.11% in Q2 2025 and -2,377.82% in Q1 2025.